Abstract
Immune checkpoint inhibitors have made significant advances in available cancer treatment options towards progression-free and overall survival in cancer patients by potentiating own anti-tumor immune response. Anti-programmed death (PD-1) and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have been increasingly associated with neurologic complications. LE is a rare complication and like many complications secondary to immunotherapy, there is no standard for evaluation and treatment. Anti-GAD65-associated LE has been associated with thymic carcinoma. We describe a patient who presented with progressive memory loss 2 weeks after her third cycle of Ipilimumab and Nivolumab with associated elevated Anti-GAD65 levels. Treatment with IVIG and PLEX led to complete resolution of her symptoms and improvement in her brain imaging and CSF findings.
Original language | English (US) |
---|---|
Pages (from-to) | 1023-1025 |
Number of pages | 3 |
Journal | Journal of Neurology |
Volume | 267 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2020 |
Keywords
- Checkpoint inhibitor
- Ipilimumab
- Limbic encephalitis
- Nivolumab
ASJC Scopus subject areas
- Neurology
- Clinical Neurology